Literature DB >> 31929794

An Overall Glance of Evidence Supportive of One-Hour and Two-Hour Postload Plasma Glucose Levels as Predictors of Long-Term Cardiovascular Events.

Baldeep K Mann1, Janpreet S Bhandohal1, Jungrak Hong1.   

Abstract

This review summarizes the vast literature describing the long-term epidemiological studies with emphasis on postprandial glucose as a stronger predictor of cardiovascular complications as compared to fasting glucose and HbA1c. Many molecular studies also supported this fact by illustrating that postchallenge hyperglycemia is associated with elevated biomarkers of systemic inflammation in the plasma and thus increasing the chances of vascular damage. Large-scale studies have proved that vascular stiffness, brachial-ankle pulse-wave velocity, carotid intima thickness, and left ventricular hypertrophy have been associated with postprandial glucose as compared to fasting glucose or glycosylated hemoglobin.
Copyright © 2019 Baldeep K. Mann et al.

Entities:  

Year:  2019        PMID: 31929794      PMCID: PMC6935819          DOI: 10.1155/2019/6048954

Source DB:  PubMed          Journal:  Int J Endocrinol        ISSN: 1687-8337            Impact factor:   3.257


1. Introduction

The cardiovascular impact of elevated postprandial glucose has been studied extensively through a significant number of prospective longitudinal, cross-sectional, molecular, and experimental studies in various parts of the world. This concept of relating the postprandial glucose to coronary and cardiovascular events began as early as 1970s with some of the prospective studies at that time. The postprandial state that has been shown to be related to cardiovascular events from time to time was either after 1 hour or 2 hours of ingestion of oral glucose load also known as the oral glucose tolerance test (OGTT). This may be related to the fact that some cases of diabetes (strong risk factor for cardiovascular mortality) can be missed if only fasting blood glucose (FBG) is used in screening [1]. Only few cross-sectional and prospective studies favor glycosylated hemoglobin (HbA1c) being superior to FBG and 2-hour plasma glucose (2 hPG) for prediction of ischemic heart disease [2]. In a cross-sectional study, elevated plasma levels on admission, HbA1c, and FBG were found to have low sensitivity to detect undiagnosed diabetes in patients with acute coronary syndrome as compared to OGTT [3]. The EUROASPIRE IV (the European Action on Secondary Prevention through Intervention to Reduce Events) cross-sectional survey of 4004 subjects in 24 European countries showed that OGTT identified a largest number of previously undiagnosed diabetic patients with established coronary artery disease [4]. In a meta-analysis showing that impaired fasting glucose was significantly associated with future risk of coronary heart disease (CHD), the subgroup analyses showed that risk of CHD was only increased in the studies which enrolled participants with increased 2 hPG and not in those which excluded them [5].

2. Pioneer Epidemiological Studies

One of the initial investigations showing the relationship of glucose tolerance to the incidence of CHD-associated death and nonfatal myocardial infarction (MI) was two cohort studies consisting of 3,267 and 1,059 Finnish men in 1972 who were followed up over a period of 5 years and the CHD-related death was significantly related to high 1-h postload blood glucose (1 hPG) level [6]. Later, another large prospective study, the Honolulu Heart Program in Hawaii, involving a 20-year follow-up of 457 migrant Japanese patients also found 1 hPG to be positively related to MI-related mortality [7]. Also, in the Honolulu program, odds ratio for 1 hPG in patients with ankle brachial index <0.9 was 1.3 (p < 0.05) and found to be predictive of peripheral vascular disease 25 years later [8]. The Helsinki Businessmen prospective study in which 610 men joined a multifactorial primary prevention trial of cardiovascular diseases revealed that 1 hPG was significantly associated with total mortality along with other traditional risk factors (smoking, blood pressure, and cholesterol) after 28 years of follow-up [9]. The evidence strengthened further in the late 1990s with the Chicago Heart association Detection Project in Industry where a 22 year-long longitudinal study of 26,753 nondiabetic men and women showed that 1 hPG level is an independent risk factor for fatal CHD [10].

3. Subsequent Epidemiological Studies Supportive of Cardiovascular Impact of Postchallenge Hyperglycemia

US National Library of Medicine (Pub Med.gov) was searched with search terms “post load glucose” and “cardiovascular”; “post load glucose” and “coronary”; “post challenge hyperglycemia” and “cardiovascular”; “post challenge hyperglycemia” and “coronary”; “post prandial glucose” and “cardiovascular”; “post prandial glucose” and “coronary”; “OGTT” and “cardiovascular”; and “OGTT” or “coronary”. Various epidemiological studies were found to be conducted from 1999 to 2019 suggesting postprandial glucose as a better predictor of cardiovascular disease independent of FBG that have been enlisted in Table 1. The median follow-up in these trials was 7.2 years with a median number of patients 1425 and median rate of 1.5. Graphical presentation of the rate ratios of studies enlisted in Table 1 has been depicted in Figure 1. Epidemiological data from 20 European studies concluded that 31% of the diabetic patients with nondiabetic fasting glucose will remain underdiagnosed if only fasting glucose criteria is used and the risk profile of the subjects with impaired fasting glucose depends on 2 hPG levels [42]. Thus, the DECODE study (Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe) has emphasized on postchallenge hyperglycemia as the main determinant of risk of cardiovascular disease (CVD) in patients with diabetes [42]. A large prospective Whitehall study involving 17,869 subjects followed up over 33 years established a linear dose-response relationship between postload plasma glucose and CHD mortality risk [14].
Table 1

Epidemiological studies describing the postprandial hyperglycemia as a predictor of cardiovascular mortality in various parts of the world for the last two decades.

No.Type of studyName of the studyTotal number of patientsDuration of follow-up (years)Subject characteristicsStudy outcome measuredRate ratio95% CI p value
1Prospective cohortSievers et al., 1999 [11]174510.6Pima Indians with type 2 diabetes ≥15 years of age2-hour postprandial glucose (2 hPG) levels were associated with death rate from cardiovascular disease (CVD)Death rate 1.21.1–1.40.007

2Prospective cohortde Vegt et al., 1999 [12]23638Dutch subjects 50–75 years without known diabetesPostload glucose predictive of increased cardiovascular mortality even within the nondiabetic rangeRelative risk (RR) 3.41.35–8.53<0.05

3Prospective cohortMeigs et al., 2002 [13]33704Subjects from the Framingham offspring study without clinical CVD or medication-treated diabetes2 hPG is associated with cardiovascular eventsRR 1.141.02–1.27Not available

4Prospective cohortBrunner et al., 2006 [14]1786933London-based male civil servants aged 40–64 years excluding those with known diabetes and with missing glucose measurements2 hPG associated with coronary heart diseaseHazard ratio (HR) 3.622.34–5.56Not available

5Prospective cohortMeisinger et al., 2006 [15]116030Randomly selected 40–59 year non-diabetic German subjects1-hour postload glucose (1 hPG) associated with all-cause mortalityHR 1.491.17–1.88Not available

6Prospective cohort (1974–1979)Nigam et al., 2007 [16]169114.7Patients with coronary artery disease (CAD) who were enrolled at 15 centers throughout North AmericaPostprandial hyperglycemia was not associated with cardiovascular mortality in patients with undiagnosed diabetesHR 0.890.59–1.36Not available

7Prospective cohortChien et al., 2008 [17]216510.5Chinese subjects in Taiwan aged ≥35 yearsPostchallenge glucose was associated with major cardiovascular eventsRR 2.051.23–3.42≤0.001

8Prospective cohortSarwar et al., 2010 [18]1856923.5Iceland subjects without history of diabetes and myocardial infarction (MI)Postload glucose associated with coronary heart diseaseHR 1.031.01–1.05Not available
9Meta-analysis of 26 western prospective cohort studiesSarwar et al., 2010 [18]12652Not applicableNot applicablePostload glucose associated with coronary heart diseaseRR 1.051.03–1.07Not available

10Prospective cohortKitada et al., 2010 [19]4222Acute MI (AMI) Japanese patients2 hPG was the only independent predictor of long-term major adverse cardiovascular events (MACE) two years after AMIOdds ratio (OR) 1.851.07–3.210.028

11Case controlShimabukuro et al., 2011 [20]287Not applicableJapanese who visited the university hospital to be checked for glucose intolerance or known type 2 diabetes were consecutively recruitedLeft ventricle dysfunction associated with impaired glucose toleranceOR 3.431.09–11.20.037

12Prospective cohort (HEART2D trial)Raz et al., 2011 [21]11152.7Patients with type 2 diabetes who survived of AMIPatients using insulin targeting the postprandial versus fasting hyperglycemia had lower cardiovascular eventsHR 0.690.49–0.960.029

13Large prospective cohort (EpiDREAM study)Anand et al., 2012 [22]18,9903.530–85 years multiethnic patients from 21 countries who had impaired glucose tolerance (IGT) and impaired fasting glucose (IFG) levels2-hour post-OGTT glucose associated with increase in risk of cardiovascular events or deathHR 1.171.13–1.22Not available

14Prospective cohortTamita et al., 2012 [23]2755.3Japanese subjects with AMIAbnormal glucose tolerance associated with MACEHR 2.651.37–5.150.004

15Prospective cohortFurtado de Souza et al., 2012 [24]14836 ± 14 monthsBrazilian subjects undergoing diabetes screening attending a primary care unit2-hour OGTT results were associated with CVDOR 1.0131.002–1.0250.024
169 Finnish and Swedish prospective cohortNing et al., 2012 [25]3743 men and 3916 women16.425 to 90 years who had fasting plasma glucose (FPG) < 6.1 mmol/l and 2 h PG < 7.8 mmol/l and free of CVD2 hPG associated with coronary heart diseaseHR 1.13 in men; 1.33 in women0.93–1.37 in men; 0.83–2.13 in womenNot available

17Prospective cohortHenareh and Agewall, 2012 [26]1236.03 ± 1.36Swedish subjects aged 31–80 years who had suffered a previous MI2 hPG was a significant predictor of cardiovascular death, recurrent MI, and unstable angina pectorisHR 1.271.00–1.62<0.05

18Prospective cohortSilbernagel et al., 2012 [27]17727.7 ± 2.0German nondiabetic subjects who were referred for angiography and whose FPG was <126 mg/dl underwent OGTTPostchallenge glucose undetected by fasting glucose and glycated hemoglobin independently predicted the cardiovascular mortalityHR 1.571.02–2.430.041

19Cross sectional (second strong heart study)Capaldo et al., 2013 [28]562Not applicableAmerican nondiabetic and nonhypertensive Indians of 45–74 years of ageBoth higher IFG and IGT levels rather than only IFG associated with left ventricular hypertrophyOR 9.762.03–46.790.004

20Prospective cohortBarzin et al., 2013 [29]37948Tehran urban subjects aged ≥40 years without history of diabetes or CVDIsolated postchallenge hyperglycemia associated with cardiovascular eventsHR 1.771.19–2.640.005

21Cross sectionalYang et al., 2013 [30]6040Not applicableChinese prediabetic subjectsCVD events associated with IGT levels compared to IFG levelsOR 2.881.36–6.010.0059

22Prospective cohortKuramitsu et al., 2013 [31]8284.3Japanese patients of stable angina undergoing percutaneous intervention (PCI)Postchallenge hyperglycemia was associated with MACEHR 1.621.07–2.530.023

23Finnish diabetes prevention prospective cohort studyLind et al., 2014 [32]50413Finnish individuals with IGT were followed up with yearly OGTT, FPG, and HbA1c2 hPG was associated with CVD eventsHR 2.191.51–3.18≤0.001
24Prospective cohortRitsinger et al., 2015 [33]167 AMI patients and 184 controls10Swedish patients up to 80 years with AMI (n = 167) and healthy controls (n = 184) with no previously known diabetesPatient with AMI having abnormal glucose tolerance after an OGTT performed at the time of discharge had higher cardiovascular mortalityHR 2.31.24–4.250.008

25aYorkshire retrospective cohortGeorge et al., 2015 [34]7683Patients without pre-existing diabetes mellitus post-MIIGT associated with increased incidence of MACEHR 1.541.06–2.240.024

25bYorkshire retrospective cohort studyGeorge et al., 2015 [34]7683Patients without pre-existing diabetes mellitus post-MINewly diagnosed diabetes associated with increased incidence of MACEHR 2.151.42–3.240.003

26Prospective cohortFaghihi-Kashani et al., 2016 [35]26077.2Patients of type 2 diabetes mellitus in Tehran2 hPG was associated with high incidence of coronary heart diseaseHR 1.641.03–2.61Not available

27Prospective cohortShahim et al., 2017 [36]4004224 European subjects aged ≥18–80 years hospitalized for a first or recurrent CAD event2 hPG associated with cardiovascular eventsHR 1.381.07–1.780.01

28Prospective cohortNielsen et al., 2017 [37]493427Swedish subjects without diabetes1 hPG predicted the cardiovascular deathHR 1.091.01–1.170.02

29Prospective cohortChattopadhyay et al., February 2018 [38]6744Post-MI survivors without known diabetes in England and WalesOnly 2 hPG predicted MACEHR 1.121.04–1.20≤0.001

30Retrospective cohortChattopadhyay et al., August 2018 [39]105640.8 monthsAcute coronary event survivors without known diabetes mellitus who had FBG and 2 hPG measured predischarge2 hPG independently predicted MACEHR 1.0911.043–1.142≤0.001

31Cross sectional (CATAMERI study)Fiorentino et al., 2019 [40]1010Not applicableNondiabetic Caucasian individuals with hbA1c <5.7%1 hPG during OGTT ≥ 155 mg/dl associated with CADOR 6.161.05–36.320.04

32Retrospective cohortChattopadhyay et al., 2019 [41]10562.8MI survivors in East yorkshire and North Lincolnshire2 hPG predicted MACE-free survivalHR 1.161.07–1.26≤0.001
Figure 1

Graphical presentation of risks, hazard ratios, odds ratios, or mortality rates per study enlisted in Table 1 in temporal order.

3.1. Postprandial State Enhances Atherosclerosis in Arteries and Has Detrimental Effects on Myocardial Function

The epidemiological studies were also supported by experimental studies which indicated that the postprandial state may affect atherosclerosis process in the arteries, thereby increasing the coronary vascular events. In European nondiabetic population of 403 subjects, multivariate analysis showed that carotid intima-media thickness was significantly increased in the top 5th quintile of 2 hPG but not the fasting glucose [43]. There was clustering of risk factors such as body mass index, waist to hip ratio, elevated triglycerides, and decreased high-density lipoprotein (HDL-cholesterol) levels in the top quintile of 2 hPG as well [43]. Another cross-sectional study of 356 participants from Pittsburgh site of the Cardiovascular Health Study measured the aortic stiffness through aortic wave pulse velocity, and after controlling age and systolic blood pressure, the strongest predictors of aortic stiffness were heart rate and 2 hPG (p=0.063) [44]. In the RIAD study (Risk factors in Impaired glucose tolerance for Atherosclerosis and Diabetes) intima-media thickness of common carotid arteries that was taken as measure of atherosclerosis was associated with 2 hPG even when HbA1c was within normal range [45]. This has formed a basis of many studies in 1990s like Diabetes Interventional Study, Kumamoto study, DIGAMI (Diabetes and Insulin-Glucose infusion in Acute Myocardial Infarction) study, and STOP-NIDDM (Study TO Prevent NIDDM) trial to control the postprandial hyperglycemia in order to prevent CVD [45]. In a randomized study where 61 patients with type 2 diabetes were followed up over 24 months and diastolic myocardial dysfunction (E′), intima media thickness and arterial stiffness were significantly higher in patients receiving only conventional insulin therapy (human insulin b.d.) vs. regimens receiving better postmeal glucose control with intensified conventional insulin therapy (lispro at meals and NPH bed time) and supplementary insulin therapy (regular insulin at meals) [46]. In a cross-sectional study from China involving 671 men and 603 women, it was found that the patients with impaired glucose tolerance after glucose challenge have higher brachial-ankle pulse wave velocity/arterial stiffness, are more insulin resistant, and have worse lipid profile [47]. A cross-sectional study of 767 never treated hypertensive subjects showed that 1 hPG of ≥155 mg/dL is a major determinant left ventricular mass index and hence left ventricular hypertrophy in hypertensive patients, that in itself is independent risk factor for cardiovascular morbidity and mortality [48]. In a cross-sectional study including 4938 subjects from China, the ones with impaired glucose tolerance and newly diagnosed diabetes, but not the isolated impaired fasting glucose, had higher brachial-ankle pulse-wave velocity and thus greater arterial stiffness [49]. In a cross-sectional study of 584 newly diagnosed hypertensive individuals, those who had normal glucose tolerance on 2 hPG but had 1 hPG ≥155 mg/dl had higher indices of vascular stiffness (pulse wave velocity, augmentation pressure, and augmentation index) that correlate with the cardiovascular risk profile [50].

3.2. Molecular Studies Relating Postprandial Effect on the Cardiovascular Profile

An experimental study showed that the concentration of soluble forms of the adhesion molecules sE-selectin and sVCAM-1 (vascular cell adhesion molecule-1), which were hypothesized as early predictors of coronary artery disease, was significantly related to postload glucose concentration in 78 men with symptoms of angina and positive exercise stress test who presented for coronary arteriography [51]. In a large observational study, it was found that the oral glucose tolerance test increases biomarkers of systemic inflammation such as hsCRP, IL-6, TNF-alpha, sICAM-1, sVCAM-1, and sE-selectin [52]. Postchallenge hyperglycemia is associated with increased generation of asymmetric dimethylarginine and reactive oxygen species that lead to decreased nitric oxide synthesis which decreases endothelial-dependent flow-mediated dilation and hence decreased vascular function [53]. In a CODAM (Cohort on Diabetes and Atherosclerosis Maastricht) study, α-dicarbonyl concentrations are correlated with glucose levels during OGTT, not with FBG or HbA1c in individuals with impaired glucose metabolism and type 2 diabetes which are associated with more vascular complications [54].

3.3. Clustering of Cardiovascular Risk Factors with Elevated Postload Glucose

A cross-sectional study of 1475 subjects of Arian ethnicity showed that cardiovascular risk factors like age, body mass index, waist circumference, blood pressure, and lipid profile (not low-HDL cholesterol) were significantly higher in normal glucose tolerance subjects with 1 hPG >155 mg/dl [55]. In a multicenter cross-sectional GENFIEV (GENetics, PHYsiopathology, and EVolution of Type 2 diabetes) study, 1 hPG >155 mg/dl showed lower insulin sensitivity, impaired β-cell function, and worse cardiovascular risk profile (glycosylated hemoglobin, blood pressure, low-density lipoprotein cholesterol, and triglyceride) [56]. In the 2005–2014 National Health and Nutrition examination survey, a cross-sectional survey of 3644 adults with prediabetes based on FBG and HbA1c, 6.9% were detected to have diabetes based on 2 hPG and were more likely to have hypertension, higher triglycerides, lower high-density lipoprotein cholesterol, and higher albuminuria [57]. In a DICAMANO study of 447 overweight/obese subjects with FBG ≤5.5 mmol/l (99 mg/dl) and BMI ≥ 25 kg/m2 who underwent a 75 g OGTT after multivariable adjustment for FBG, smoking, and physical activity level, the odds ratio (95% confidence intervals) was higher for the presence of postprandial hyperglycemia for anthropometric indices of central fat distribution (neck circumference, waist circumference, and waist-to-height ratio) [58].

3.4. Postprandial Glucose Helps to Predict Cardiovascular Disease in Patients with Prediabetes

There has been substantial evidence found by Bergman et al. that led them to support the idea of redefining current diagnostic criteria for prediabetes with elevated 1 hPG level. Among patients having normal glucose tolerance during the OGTT, 1 hPG was found to be highly predictive for detecting progression to diabetes and micro- and macrovascular complications [59]. As compared with subjects with 1 hPG <155 mg/dl, individuals with 1 hPG ≥155 mg/dl exhibited a significantly worse cardiometabolic profile, both in the group without diabetes (HbA1c <5.7%) and in the group with prediabetes (HbA1c 5.7–6.4%) [60]. In the Finnish Diabetes Prevention prospective cohort study, when 504 individuals with IGT were followed up over 13 years with yearly evaluations with OGTT, FPG, and HbA1c levels, it was found that 2 hPG was associated with increased risk of CVD. This supports the use of 2 hPG in screening for prediabetes and monitoring glycaemic levels of people with prediabetes [32]. Both IFG and IGT are associated with increased cardiovascular risk as assessed by serum lipid and hsCRP levels but IGT being characterized by a more atherogenic risk profile than IFG [61]. In the EpiDREAM study, the patients from 21 countries who had IGT and IFG levels were followed up over 3.5 years, and 2 hPG was associated with increased risk of cardiovascular events [22]. In a Chinese cross-sectional study involving prediabetic subjects, odds of developing the CVD events were associated with IGT levels rather than IFG levels [30].

4. Conclusion

The concept of relating the postprandial glucose as opposed to fasting glucose to coronary and cardiovascular events began as early as 1970s. This later on formed the basis of large-scale prospective studies that showed that OGTT identifies a largest number of previously undiagnosed diabetic patients with established coronary artery disease. Postprandial glucose was found to be significantly related to myocardial infarction-related mortality in nondiabetic and prediabetic patients. Additionally, studies demonstrated that controlling the postprandial hyperglycemia can prevent cardiovascular disease even in nondiabetic subjects. Biochemical markers of vascular inflammation which were hypothesized as early predictors of coronary artery disease were significantly related to postload glucose concentrations. Cardiovascular risk factors like age, body mass index, waist circumference, blood pressure, and lipid profile were significantly higher in patients with elevated postprandial glucose. The review of these studies suggests the need for reconsideration of factors on the basis of which diabetes is managed in the primary-care clinics. The patients visiting the doctor's office with their fingerstick log are usually uncertain whether they should check fasting sugars or postprandial. Some of these patients are even unsure about the duration between their meals and checking the sugar. They should be counseled about the importance of each of these blood glucose values (fasting vs. one-hour and two-hour postload glucose) and elevation of which of those values is more detrimental for their cardiovascular health. There has also been suggestion by few authors regarding revising the diagnostic criteria for prediabetes based solely on postprandial glucose for early avoidance of risk factors leading to significant cardiovascular morbidity and mortality.
  3 in total

1.  One-Hour Post-Load Plasma Glucose Levels are Associated with Early Arterial Stiffness in Subjects with Different Glucose Tolerance.

Authors:  Rui Wang; Xiao-Li Liu; Xiao-Jiao Jia; Yan Liu; Qiang Lu
Journal:  Diabetes Metab Syndr Obes       Date:  2022-05-17       Impact factor: 3.249

2.  A Protein/Lipid Preload Attenuates Glucose-Induced Endothelial Dysfunction in Individuals with Abnormal Glucose Tolerance.

Authors:  Domenico Tricò; Lorenzo Nesti; Silvia Frascerra; Simona Baldi; Alessandro Mengozzi; Andrea Natali
Journal:  Nutrients       Date:  2020-07-10       Impact factor: 5.717

3.  One-hour post-load glucose improves the prediction of cardiovascular events in the OPERA study.

Authors:  Anni Saunajoki; Juha Auvinen; Aini Bloigu; Olavi Ukkola; Sirkka Keinänen-Kiukaanniemi; Markku Timonen
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.